Marto João Pedro, Qureshi Muhammad, Nagel Simon, Nogueira Raul G, Henon Hilde, Tomppo Liisa, Ringleb Peter Arthur, Haussen Diogo C, Abdalkader Mohamad, Puetz Volker, Zaidat Osama O, Demeestere Jelle, Ramos João Nuno, Ribo Marc, Olive-Gadea Marta, Mohammaden Mahmoud H, Ortega-Gutierrez Santiago, Sheth Sunil, Yamagami Hiroshi, Dusart Anne, Raymond Jean, Caparros Francois, Kaiser Daniel, Tanaka Kanta, Virtanen Pekka, Puri Ajit S, Siegler James Ernest, Zaidi Syed F, Jumaa Mouhammad Aghiad, Lin Eugene, Requena Manuel, Michel Patrik, Winzer Simon Mathias, Klein Piers, Nannoni Stefania, Bellante Flavio, Salazar-Marioni Sergio, Galecio-Castillo Milagros, Wouters Anke, Ventura Rita, Mujanovic Adnan, Shu Liqi, Castonguay Alicia C, Jesser Jessica, Masoud Hesham E, Kaesmacher Johannes, Hu Wei, Roy Daniel, Yaghi Shadi, Asdaghi Negar, Strambo Davide, Lemmens Robin, Strbian Daniel, Cordonnier Charlotte, Möhlenbruch Markus, Nguyen Thanh N
Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Portugal.
Department of Radiology, Radiation Oncology, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, MA.
Neurology. 2025 Apr;104(7):e213442. doi: 10.1212/WNL.0000000000213442. Epub 2025 Mar 20.
There is uncertainty about whether patients with an anterior circulation large vessel occlusion (LVO) and a low NIH Stroke Scale (NIHSS) score (≤5) benefit from endovascular therapy (EVT) in the late time window (6-24 hours). We compared the clinical outcomes of these patients receiving EVT with those receiving medical management (MM).
The CT for Late Endovascular Reperfusion multinational cohort study was conducted at 66 sites across 10 countries from January 2014 to May 2022. This subanalysis included consecutive patients with late-window stroke due to an anterior circulation LVO, defined as occlusion of the internal carotid artery or proximal middle cerebral artery (M1/M2 segments), and a baseline NIHSS score ≤5 who received EVT or MM alone. The primary end point was a 90-day ordinal shift in the modified Rankin Scale (mRS) score. Secondary outcomes were 90-day excellent outcome (defined as mRS scores 0-1 or return to baseline mRS score in patients with a prestroke mRS score >1) and favorable outcome (defined as mRS scores 0-2 or return to baseline mRS score in patients with prestroke mRS score >2). Safety outcomes were symptomatic intracranial hemorrhage and 90-day mortality. We used ordinal and binary logistic regression models to test for outcome differences.
Among 5,098 patients, 318 patients were included (median [interquartile range] age 67 [56-76] years; 149 [46.9%] were female; baseline NIHSS score was 4 [2-5]). A total of 202 patients (63.5%) received EVT and 116 MM (36.5%). There was no difference in favorable 90-day ordinal mRS score shift (adjusted common odds ratio [OR] 0.77, 95% CI 0.45-1.32), excellent outcome (adjusted OR 0.86, 95% CI 0.49-1.50), or favorable outcome (adjusted OR 0.72, 95% CI 0.35-1.50) in the EVT group compared with MM. Symptomatic intracranial hemorrhage risk (adjusted OR 3.40, 95% CI 0.84-13.73) and mortality at 90 days (adjusted OR 2.44, 95% CI 0.60-10.02) were not statistically different between treatment groups.
In patients with an anterior LVO and low NIHSS score in the 6-24-hour time window, there was no statistical difference in disability outcomes or intracranial bleeding risk between patients treated with EVT compared with MM. The retrospective and observational design limits our findings. Ongoing randomized controlled trials will provide further insight.
This study provides Class III evidence that in adult patients with anterior circulation LVO and low NIHSS score (≤5) presenting in the late time window (6-24 hours), EVT does not improve clinical outcome vs MM.
This study was registered at clinicaltrials.gov under NCT04096248.
对于前循环大血管闭塞(LVO)且美国国立卫生研究院卒中量表(NIHSS)评分较低(≤5分)的患者,在晚期时间窗(6 - 24小时)内是否能从血管内治疗(EVT)中获益尚不确定。我们比较了接受EVT治疗的这些患者与接受药物治疗(MM)的患者的临床结局。
晚期血管内再灌注CT多国队列研究于2014年1月至2022年5月在10个国家的66个地点进行。该亚分析纳入了因前循环LVO导致的晚期卒中连续患者,定义为颈内动脉或大脑中动脉近端(M1/M2段)闭塞,且基线NIHSS评分≤5分,单独接受EVT或MM治疗的患者。主要终点是改良Rankin量表(mRS)评分在90天时的序贯变化。次要结局是90天时良好结局(定义为mRS评分为0 - 1分或卒中前mRS评分>1分的患者恢复到基线mRS评分)和有利结局(定义为mRS评分为0 - 2分或卒中前mRS评分>2分的患者恢复到基线mRS评分)。安全性结局是有症状性颅内出血和90天死亡率。我们使用序贯和二元逻辑回归模型来检验结局差异。
在5098例患者中,纳入了318例患者(年龄中位数[四分位间距]为67[56 - 76]岁;149例[46.9%]为女性;基线NIHSS评分为4[2 - 5]分)。共有202例患者(63.5%)接受了EVT治疗,116例接受了MM治疗(36.5%)。与MM组相比,EVT组在90天时mRS评分的有利序贯变化(校正共同比值比[OR]为0.77,95%可信区间[CI]为0.45 - 1.32)、良好结局(校正OR为0.86,95%CI为0.49 - 1.50)或有利结局(校正OR为0.72,95%CI为0.35 - 1.50)方面无差异。治疗组之间有症状性颅内出血风险(校正OR为3.40,95%CI为0.84 - 13.73)和90天死亡率(校正OR为2.44,95%CI为0.60 - 10.02)无统计学差异。
在6 - 24小时时间窗内前循环LVO且NIHSS评分较低的患者中,与MM治疗相比,接受EVT治疗的患者在残疾结局或颅内出血风险方面无统计学差异。回顾性和观察性设计限制了我们的研究结果。正在进行的随机对照试验将提供进一步的见解。
本研究提供了III类证据,即在晚期时间窗(6 - 24小时)出现前循环LVO且NIHSS评分较低(≤5分)的成年患者中,与MM相比,EVT并不能改善临床结局。
本研究在clinicaltrials.gov上注册,注册号为NCT04096248。